Alliance Pharma (APH)
market vs.
industry GROWTH & VALUE
| 12m Forecast Rolling | ||||
| PE Ratio (f) | 10.3 |
|
|
|
| PEG Ratio (f) |
|
|
||
| EPS Growth (f) | % |
|
|
|
| Dividend Yield (f) | % |
|
|
|
| Valuation (ttm) | ||||
| Price to Book Value | 1.75 |
|
|
|
| Price to Tang. Book |
|
|
||
| Price to Free Cashflow |
|
|
||
| Price to Sales |
|
|
||
| EV to EBITDA |
|
|
||
market vs.
industry QUALITY
| Year End 31st Dec | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013E | 2014E | CAGR / Avg | |
| Revenue | £m | |||||||||
| Operating Profit | £m | |||||||||
| Net Profit | £m | |||||||||
| EPS Reported | p | |||||||||
| EPS Normalised | p | |||||||||
| EPS Growth | % | |||||||||
| PE Ratio | x | |||||||||
| PEG | x | |||||||||
| Profitability | ||||||||||
| Operating Margin | % | |||||||||
| ROA | % | |||||||||
| ROCE | % | |||||||||
| ROE | % | |||||||||
| Cashflow | ||||||||||
| Op. Cashflow ps | p | |||||||||
| Capex ps | p | |||||||||
| Free Cashflow ps | p | |||||||||
| Last ex-div: 12th Jun, paid: 11th Jul more... Dividends | ||||||||||
| Dividend ps | p | |||||||||
| Dividend Growth | % | |||||||||
| Dividend Yield | % | |||||||||
| Dividend Cover | x | |||||||||
| Balance Sheet | ||||||||||
| Cash etc | £m | |||||||||
| Working Capital | £m | |||||||||
| Net Fixed Assets | £m | |||||||||
| Net Debt | £m | |||||||||
| Book Value | £m | |||||||||
| Average Shares | m | |||||||||
| Book Value ps | p | +39.0% | ||||||||
FINANCIAL BRIEF: For the fiscal year ended 31 December 2012, Alliance Pharma plc revenues decreased 2% to L44.9M. Net income increased 1% to L8.7M. Revenues reflect Ireland segment decrease of 24% to L4.3M, United Kingdom segment decrease of 2% to L36.7M. Net Income benefited from Amortisation decrease of 22% to L573K (expense), Forien exchange rate movement increase from L29K (expense) to L30K (income). Dividend per share remained flat at L0.01. more »
| Leverage (ttm) | Total | Ex Intang | |||
| Gross Gearing | % | ||||
| Net Gearing | % | ||||
| Cash / Assets | % | ||||
| Liquidity (ttm) | ||
| Current Ratio | ||
| Quick Ratio | ||
| Interest Cover | ||
| Efficiency (ttm) | ||
| Asset Turnover | ||
| Rec's Turnover | ||
| Stock Turnover | ||
market vs.
industry RECENT HISTORY
| Latest interim period (ended 31st Dec '12) vs. prior year | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| 3yr Average Annualised | ||||
| Sales Growth | % |
|
|
|
| EPS Growth | % |
|
|
|
| DPS Growth | % |
|
|
|
BROKER CONSENSUS & FORECAST TREND
| Recommendation: | Strong Sell | Sell | Hold | Buy | Strong Buy |
|---|---|---|---|---|---|
| No. of Analysts: | 0 | 0 | 4 | 1 | 1 |
Alliance Pharma plc is engaged in the acquisition, marketing and distribution of pharmaceutical products. It sells a range of over 50 acquired and licensed products across a range of therapeutic categories. The Company has products in two areas of specialization, Dermatology and Oncology that are promoted. Its products include Acnisal, Alphaderm, Aquadrate, Atarax, Quinoderm, Occlusal, Timodine, Meted, Naseptin, Pentrax, Permitabs, Isotretinoin, Hydromol, Dermamist, ImmuCyst, Gelclair and Procarbazine. On December 16, 2011, it acquired the brands Quinoderm and Ceanel from Ferndale Pharmaceuticals Limited. On October 31, 2011, it disposed of Biorphen and Broflex. In August 2012, its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired the antimalarial brands Paludrine, Avloclor and Savarine from AstraZeneca UK Limited. In October 2012, the Company’s subsidiary, Alliance Pharmaceuticals Limited acquired Opus Group Holdings Limited.
Directors: John Dawson (CEO) , Richard Wright (Fin. Dir.) , Anthony Booley (Exec. Dir.) , Peter Butterfield (Exec. Dir.) , Sarah Robinson (Secy.) ,
No. of Employees: 63 No. of Shareholders: 584
| Last Annual | December 31st, 2012 |
| Last Interim | December 31st, 2012 |
| Shares in Issue | 247,450,508 |
| Free Float | 152.9m (61.8%) |
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Index | FTSE Aim All Share, |
| Exchange |
London Stock Exchange (AIM) |
| Eligible for | an ISA? a SIPP? |
| Address | Avonbridge House 2 Bath Road, CHIPPENHAM, SN15 2BB, United Kingdom |
| Web | http://www.alliancepharma.co.uk |
| Phone | +44 1249 466966 |
| Contact | Madeleine Scott (Secy.) |
| Registrar | Capita Registrars |
| Auditors | Grant Thornton UK LLP |
| Wed 7:00am | Proactive Investors Presentation |
| 13th May | CULS Conversion and Additional Listing |
| 23rd Apr | CULS Conversion and Additional Listing |
| 15th Apr | CULS Conversion and Additional Listing |
| 8th Apr | CULS Conversion and Additional Listing |
| 21st Mar | Preliminary Results |
Recent ↓
